Capital News

Hypertension Pipeline Insight and Clinical Trial Phases Report | 100+ Companies and 100+ Drugs

 Breaking News
  • No posts were found

Hypertension Pipeline Insight and Clinical Trial Phases Report | 100+ Companies and 100+ Drugs

January 12
21:30 2023
Hypertension Pipeline Insight and Clinical Trial Phases Report | 100+ Companies and 100+ Drugs

DelveInsight’s, “Hypertension Pipeline Insight, 2023,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including Hypertension clinical trials and nonclinical stage products. It also covers the Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Hypertension Pipeline Report

 

  • DelveInsight’s Hypertension pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for hypertension treatment.

 

  • The leading Hypertension Companies are working to develop drug candidates to improve the Hypertension treatment landscape include Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision, Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics, Inc., Aadi Bioscience, Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma, LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio, Inc., Santen Pharmaceutical,  VivaVision Biotech, Mitsubishi Chemical Group Corporation., Idorsia Pharmaceuticals, United Therapeutics Corporation, VIVUS LLC., PhaseBio Pharmaceuticals, Vascular Biosciences, CAR peptide, Liquidia Corporation, Centessa Pharmaceuticals, Claritas Pharmaceuticals, Halo Biosciences, PulmoSIM Therapeutics, Keros Therapeutics, and others.

 

  • Promising Hypertension Pipeline in various stages of development include Firibastat, Baxdrostat (CIN-107), MLS-101, Zilebesiran (ALN-AGT), Ifetroban, IONIS-AGT-LRx, QLS-101, ID140009, KBP-5074, AER-90, ION904, TPN171H, FM101, AJU-C52L, T4030, L606, AV-101 , CKD-351, ABI-009, WB007, DE-130A, OTX-TIC, PRM-125, LivaloVA, NCX 470, RT234, PA5346, PHP-201, LTP001, CS1, TRC150094, JV-GL1, BI 685509, MK-5475, AGN-193408, Sotatercept, HCP1803, GB002, SPH3127, Treprostinil Palmitil, GMA301, rodatristat ethyl, BAY1237592, PRO-122,  VVN-539, Ralinepag, Tacrolimus, PB6440, MGX292,  KER-012, and others.

 

  • The Hypertension Companies and academics that are working to assess challenges and seek opportunities that could influence Hypertension R&D. The Hypertension pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

To know more about the latest breakthrough in the Hypertension Treatment Landscape @ Hypertension Pipeline Outlook Report

 

Hypertension Overview

 

High blood pressure (BP), or hypertension, is defined by two levels by 2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines: (1) elevated BP, with a systolic pressure (SBP) between 120 and 129 mm Hg and diastolic pressure (DBP) less than 80 mm Hg, and (2) stage 1 hypertension, with an SBP of 130 to 139 mm Hg or a DBP of 80 to 89 mm Hg. Hypertension is the most common primary diagnosis in the United States. It affects approximately 86 million adults (≥20 years) in the United States and is a major risk factor for stroke, myocardial infarction, vascular disease, and chronic kidney disease. Hypertension is defined as a systolic blood pressure (SBP) of 140 mm Hg or more, or a diastolic blood pressure (DBP) of 90 mm Hg or more, or taking antihypertensive medication. Hypertension may be primary, which may develop as a result of environmental or genetic causes, or secondary, which has multiple etiologies, including renal, vascular, and endocrine causes. Primary or essential hypertension accounts for 90-95% of adult cases, and secondary hypertension accounts for 2-10% of cases. The evaluation of hypertension involves accurately measuring the patient’s blood pressure, performing a focused medical history and physical examination, and obtaining results of routine laboratory studies.

 

Recent Developmental Activities in the Hypertension Treatment Landscape

 

  • In the second quarter of 2022PhaseBio completed the development and optimization of a robust manufacturing process to support anticipated upcoming proof-of-concept trials, positioning the program for initial GMP manufacturing runs in the fourth quarter of 2022. PB6440 is a highly selective aldosterone synthase inhibitor in development to target treatment resistant hypertension and other indications where elevated aldosterone is known to contribute to disease process, such as uncontrolled hypertension, chronic kidney disease, and heart failure.

 

  • In July 2022Invex Therapeutics received approval to commence the Phase III IIH EVOLVE clinical trial of Presendin to treat idiopathic intracranial hypertension (IIH) patients in Australia. The approvals include those from Human Research Ethics Committee (HREC) and the clearance for Clinical Trial Notification (CTN) scheme by the Australian Therapeutic Goods Administration (TGA). Developed by PeptronPresendin is a sustained release (SR) Exenatide microsphere formulation intended to be administered subcutaneously once a week.

 

  • In June 2022, Attgeno AB announced that it received approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start a Phase II clinical trial of its lead drug candidate Supernitro as a potentially lifesaving treatment for patients with acute pulmonary hypertension after cardiac surgery.

 

  • In June 2022Gossamer Bio, Inc. announced the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib was an effective treatment of severe PAH in two animal models, with improved cardiopulmonary hemodynamics, reduction in NT-proBNP, reverse remodeling of pulmonary vascular pathology, and improvement in inflammatory biomarkers. Seralutinib showed greater efficacy compared to imatinib in a preclinical study.

 

  • In May 2022Idorsia Ltd announced positive top-line results of PRECISION, the Phase III study investigating aprocitentan, Idorsia’s dual endothelin receptor antagonist, for the treatment of patients whose blood pressure is not adequately controlled despite receiving at least triple antihypertensive therapy – known as resistant hypertension. Aprocitentan significantly reduced blood pressure when added to standardized combination background antihypertensive therapy in patients with resistant hypertension over 48 weeks of treatment.

 

  • In May 2022United Therapeutics received the US Food and Drug Administration approval for its therapeutic Tyvaso DPI. Tyvaso DPI marks the first approval of a dry powder inhaler for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). United determined that inhalation of Tyvaso DPI is one of the easiest ways for patients to administer a prostacyclin or the treatment for PAH.

 

  • In February 2022, Ferrer strengthened its focus on pulmonary vascular and interstitial lung diseases, as well as neurological disorders, by signing of a distribution agreement with United Therapeutics Corporation for Tyvaso (treprostinil) inhalation solution – a pharmaceutical drug-device combination product for the treatment of WHO Group 3 pulmonary hypertension associated with interstitial lung disease (PH-ILD).

 

Learn more about the Hypertension Emerging Therapies @ Hypertension Ongoing Clinical Trials Analysis

 

Hypertension Emerging Drugs Profile

 

Firibastat: Quantum Genomics

The firibastat product (initially named QGC001 or RB150) is the first BAPAI drug candidate selected by Quantum Genomics. The product firibastat is a prodrug which releases the product EC33, a selective and specific inhibitor of Aminopeptidase A, in the brain, and thus prevents the production of Angiotensin III in the brain. Due to its unique mechanism of action, firibastat represents an alternative therapeutic approach that may interfere with the mechanisms involved in the genesis and maintenance of excessively high blood pressure in hypertensive patients, especially those with a particular hormonal profile, characterized by a lowered renin and high vasopressin concentration. 

 

Baxdrostat (CIN-107): CinCor Pharma

Baxdrostat (CIN-107) selectively targets aldosterone synthase, which is encoded by the CYP11B2 gene. Importantly, it has low affinity for 11ß-hydroxylase, the enzyme responsible for cortisol synthesis, which is encoded by the CYP11B1 gene. In multiple preclinical in vivo studies, baxdrostat (CIN-107) significantly lowered aldosterone levels without affecting cortisol levels, across a wide range of doses. Similar observations were made in multiple Phase 1 clinical trials in healthy volunteers. Currently, it is in Phase II stage of clinical trial evaluation to treat Hypertension. 

 

MLS-101: Mineralys Therapeutics

MLS-101 is a highly selective aldosterone synthase inhibitor designed to address elevated aldosterone, an underlying cause of hypertension prevalent in at least 25% of all hypertensive patients. MLS-101 has demonstrated excellent selectivity for the reduction of aldosterone without effecting other hormones like cortisol. MLS-101 selectivity holds the potential for targeted treatment of blood pressure in hypertension patients with elevated aldosterone production. 

 

Zilebesiran (ALN-AGT): Alnylam Therapeutics

Zilebesiran (ALN-AGT01) is a subcutaneously administered, investigational RNAi therapeutic targeting angiotensinogen (AGT) in development for the treatment of hypertension in high unmet need populations. Zilebesiran utilizes the company’s Enhanced Stabilization Chemistry Plus (ESC+)-GalNAc delivery platform. Currently, it is in Phase II stage of clinical trial evaluation to treat Hypertension.

 

IONIS-AGT-LRx: Ionis Pharmaceuticals

IONIS-AGT-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of angiotensinogen to decrease blood pressure in patients with treatment resistant hypertension (TRH). Despite availability of generic antihypertensive agents, TRH is a major contributor to cardiovascular and renal disease. Inhibiting the renin-angiotensin-aldosterone system (RAAS) is a well-established method of treating hypertension and complications of hypertension. While angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are widely used, many patients with high blood pressure are not well controlled by these treatment options. Angiotensinogen, the target of IONIS-AGT-LRx, is upstream of ACE inhibitors and ARBs in the RAAS pathway. Therefore, reducing angiotensinogen levels has the potential to decrease blood pressure in patients whose blood pressure is not adequately controlled by currently available treatment options. Furthermore, inhibiting angiotensinogen, which is made in the liver, may maintain renal compensatory mechanisms, which could lead to fewer side effects compared to current standard of care.

 

Hypertension Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Hypertension. The companies which have their Hypertension drug candidates in the most advanced stage, i.e. phase III include, Reata Pharmaceuticals.

 

Discover more information about the Hypertension Unmet Needs, Market Drivers, and Barriers @ Hypertension Treatment Landscape

 

Scope of the HypertensionPipeline Report

  • Coverage- Global
  • Hypertension Companies- Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision, Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics, Inc., Aadi Bioscience, Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma, LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio, Inc., Santen Pharmaceutical,  VivaVision Biotech, Mitsubishi Chemical Group Corporation., Idorsia Pharmaceuticals, United Therapeutics Corporation, VIVUS LLC., PhaseBio Pharmaceuticals, Vascular Biosciences, CAR peptide, Liquidia Corporation, Centessa Pharmaceuticals, Claritas Pharmaceuticals, Halo Biosciences, PulmoSIM Therapeutics, Keros Therapeutics, and others yH

 

  • Hypertension Pipeline Therapies-  Firibastat, Baxdrostat (CIN-107), MLS-101, Zilebesiran (ALN-AGT), Ifetroban, IONIS-AGT-LRx, QLS-101, ID140009, KBP-5074, AER-90, ION904, TPN171H, FM101, AJU-C52L, T4030, L606, AV-101 , CKD-351, ABI-009, WB007, DE-130A, OTX-TIC, PRM-125, LivaloVA, NCX 470, RT234, PA5346, PHP-201, LTP001, CS1, TRC150094, JV-GL1, BI 685509, MK-5475, AGN-193408, Sotatercept, HCP1803, GB002, SPH3127, Treprostinil Palmitil, GMA301, rodatristat ethyl, BAY1237592, PRO-122,  VVN-539, Ralinepag, Tacrolimus, PB6440, MGX292,  KER-012, and others.

 

  • Hypertension Segmentation: Phases, Molecule Type, Mechanism of Action, Route of Administration, Product Type

 

Table of Content

  1. Introduction
  2. Hypertension Executive Summary
  3. Hypertension: Overview
  4. Hypertension Pipeline Therapeutics
  5. Hypertension Therapeutic Assessment
  6. Hypertension – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Firibastat: Quantum Genomics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Baxdrostat (CIN-107): CinCor Pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ID-140009: IlDong Pharmaceutical
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. CKD 331: Chong Kun Dang
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Hypertension Key Companies
  21. Hypertension Key Products
  22. Hypertension- Unmet Needs
  23. Hypertension- Market Drivers and Barriers
  24. Hypertension- Future Perspectives and Conclusion
  25. Hypertension Analyst Views
  26. Hypertension Key Companies
  27. Appendix

 

For further information on the hypertension pipeline therapeutics, reach out to Hypertension Market Drivers and Barriers

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/